Legato Capital Management LLC Cuts Position in Repligen Co. (NASDAQ:RGEN)

Legato Capital Management LLC lowered its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 31.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,940 shares of the biotechnology company's stock after selling 3,630 shares during the period. Legato Capital Management LLC's holdings in Repligen were worth $1,143,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 114 shares during the period. UMB Bank n.a. raised its holdings in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after buying an additional 130 shares during the period. Creative Planning raised its holdings in Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company's stock valued at $762,000 after buying an additional 1,259 shares during the period. NBC Securities Inc. raised its holdings in Repligen by 92.2% in the 3rd quarter. NBC Securities Inc. now owns 2,931 shares of the biotechnology company's stock valued at $436,000 after buying an additional 1,406 shares during the period. Finally, nVerses Capital LLC purchased a new stake in Repligen in the 3rd quarter valued at about $45,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of Repligen stock traded up $0.75 during trading hours on Friday, hitting $146.92. 402,981 shares of the company were exchanged, compared to its average volume of 563,368. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The business has a 50-day moving average of $155.42 and a 200-day moving average of $149.08. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -397.07, a P/E/G ratio of 4.54 and a beta of 0.99.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research analyst reports. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. HC Wainwright lowered their price objective on Repligen from $240.00 to $180.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Finally, Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating for the company. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $182.91.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.